Clinical Study Finds BioE, Inc. (Formally known as BioErgonomics)'s PrepaCyte-CB Significantly Improves Cell Recoveries from Cord Blood

ST. PAUL, Minn.--(BUSINESS WIRE)--BioE®, Inc., a biomedical company that provides enabling, high-quality human stem cells for drug discovery and therapeutic research, announced today its PrepaCyte®-CB Umbilical Cord Blood Processing System significantly improves the recovery of therapeutically important total nucleated cells (TNC) and white blood cells (WBC) from human umbilical cord blood when compared to traditional hetastarch-based cord blood processing methods, according to the results of a multi-site, comparative, in-vitro clinical study.